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ABSTRACT
Administration of adipose-derived stromal/stem cells (ASCs) represents a promising therapeutic
approach for autoimmune diseases since they have been shown to have immunomodulatory properties. The uncultured, nonexpanded counterpart of ASCs, the stromal vascular fraction (SVF), is
composed of a heterogeneous mixture of cells. Although administration of ex vivo culture-expanded
ASCs has been used to study immunomodulatory mechanisms in multiple models of autoimmune
diseases, less is known about SVF-based therapy. The ability of murine SVF cells to treat myelin
oligodendrocyte glycoprotein35–55-induced experimental autoimmune encephalitis (EAE) was compared with that of culture-expanded ASCs in C57Bl/6J mice. A total of 1 ⴛ 106 SVF cells or ASCs were
administered intraperitoneally concomitantly with the induction of disease. The data indicate that
intraperitoneal administration of ASCs significantly ameliorated the severity of disease course. They
also demonstrate, for the first time, that the SVF effectively inhibited disease severity and was
statistically more effective than ASCs. Both cell therapies also demonstrated a reduction in tissue
damage, a decrease in inflammatory infiltrates, and a reduction in sera levels of interferon-␥ and
interleukin-12. Based on these data, SVF cells effectively inhibited EAE disease progression more
than culture-expanded ASCs. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:789 –796

INTRODUCTION
Multiple sclerosis (MS) is an autoimmune disease
characterized by inflammatory demyelinating lesions, extensive mononuclear cell infiltration
into the central nervous system (CNS), and loss of
motor function. Despite improved understanding of the mechanisms by which MS is manifested, current treatment options for this disease (such as interferon-␤-1a, interferon-1␤,
glatiramer acetate, fingolimod, mitoxantrone,
and natalizumab) have limited efficacy in providing symptomatic relief and complete remission,
especially in patients affected with the chronic
form of MS [1, 2]. The application of adult stem
cells as a potential treatment in MS patients has
been of recent interest, especially for patients
who do not respond to the pharmacologic immunosuppression regimens with steroids or corticotropin.
Adipose tissue makes up one of the largest
organs in the body and serves as an important
endocrine organ regulating many facets of homeostasis [3–5]. Made up of mature adipocytes
and other nonadipocyte cells, adipose tissue can
be manually disrupted and/or treated with colla-

genase to isolate the stromal vascular fraction
(SVF). Although not a fully defined cell population, the SVF includes vascular smooth muscle
cells, fibroblasts, mast cells, macrophages, lymphocytes, endothelial cells, preadipocytes, and
adipose-derived stromal/stem cells (ASCs) [5–
10]. There is an increasing interest in the biology
and therapeutic potential of SVF because of the
direct and rapid isolation procedure in a xenobiotic-free environment [9, 11–13].
The SVF can also be cultured in plasticware to
select and expand ASCs. ASCs are a fibroblast-like
adherent cell population; these cells maintain
their characteristics for several passages and can
be induced to differentiate into several cell types
in vitro, including adipocytes, chondrocytes, osteoblasts, cardiomyocytes, smooth muscle cells,
hepatic cells, endothelial cells, and neuronal-like
cells [14 –22]. Comparable to the better studied
bone marrow stromal cells (BMSCs), ASCs have
similar self-renewal abilities, common surface
epitopes, growth kinetics, and cytokine expression profiles [4, 14, 23–25]. Whereas the harvesting of BMSCs has been associated with morbidity, pain, and low yield, ASCs can be obtained at a
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high yield (the yield of stem cells per tissue volume is 100 –500fold higher in adipose tissue than bone marrow) with minimal
discomfort under local anesthesia [11, 26 –28]. In addition, recent data indicate that ASCs are potently immunomodulatory,
making them an appealing candidate for regenerative medicine
and tissue engineering [4, 29].
Both ASCs and SVF cells have been used clinically to treat
acute and chronic diseases afflicting a range of tissues and organs, including soft tissue defects, breast reconstruction, and
autoimmune disease [3, 11]. Anti-inflammatory and regenerative effects of nonexpanded SVF cells have yielded promising
results in canine osteoarthritis and equine tendon ligament injuries [30]. With the encouraging outcomes in clinical work, it is
essential to examine the effects and mechanisms of SVF and ASC
treatment in a murine model. The myelin oligodendrocyte glycoprotein (MOG)35–55-induced experimental autoimmune encephalomyelitis (EAE) in C57Bl/6J mice correlates to chronic, progressive MS and is an appropriate model to investigate the effects of
treatment with ASCs or SVF [31, 32]. Although it has been reported that mesenchymal lineage stem cells from the bone marrow have a therapeutic impact in the EAE model, to date, only a
single study has investigated murine ASCs, and SVF has not been
assessed [33–38]. The goal of this study was to directly compare
SVF cells with ASCs as interventions for disease progression in
the EAE model.

MATERIALS AND METHODS
Cell Isolation and Culture
Isolation of Stromal Vascular Fraction
Subcutaneous white adipose tissue was collected from male enhanced green fluorescence protein (eGFP) transgenic mice
(C57Bl/6-Tg(UBC-GFP)30Scha/J strain; Jackson Laboratory, Bar
Harbor, ME, http://www.jax.org), ranging in age from 2 to 6
months. Adipose tissue was washed in Hanks’ balanced saline
solution (HBSS; Life Technologies, Grand Island, NY, http://www.
lifetech.com), minced with a scalpel, and treated with 0.1% (wt/
vol) collagenase type I (Sigma-Aldrich, St. Louis, MO, http://
www.sigmaaldrich.com) in HBSS for 2 hours, while shaking at
160 rpm at 37°C. The collagenase was neutralized with prewarmed complete culture medium (CCM) that consisted of Dulbecco’s Modified Eagle Medium:Nutrient Mixture F-12 (Life
Technologies), 20% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, http://www.atlantabio.com), 100 units/ml penicillin (Life Technologies), 100 g/ml streptomycin (Life Technologies), and 2 mM L-glutamine (Life Technologies). Digested
tissue was filtered through a 70-m-pore cell strainer (Becton, Dickinson and Company, Franklin Lakes, NJ, http://www.
bd.com) to remove debris. Cells were spun at 400g for 10
minutes, and cell numbers and viability were counted with
trypan blue.

Isolation and Expansion of ASCs
The stromal vascular fraction was plated in CCM in a 75-cm2 flask
(Corning Enterprises, Corning, NY, http://www.corning.com)
and incubated at 37°C with 5% humidified CO2. After 24 hours,
nonadherent cells were removed by washing with phosphatebuffered saline (PBS) and fresh CCM. When cells (passage 0)
reached 70%– 80% confluence, cells were subcultured by lifting
with 0.25% trypsin/1 mM EDTA (Gibco, Grand Island, NY, http://
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www.invitrogen.com) and plated (passage 1) at 100 cells per cm2
in CCM on a 150-cm2 tissue culture dish (Nunc, Rochester, NY,
http://www.nuncbrand.com). Medium was replaced every 3– 4
days, and cultures were split when cells reached 70% confluence.
For all experiments, subconfluent cells (ⱕ70% confluent) between passage 2 and passage 6 were used.

Colony-Forming Unit Assay
ASCs were plated at 100 cells on a 10-cm2 plate in CCM and
incubated for 14 days at 37°C with 5% humidified CO2. Plates
were then rinsed three times with PBS, and 3 ml of a 3% crystal
violet solution (Sigma-Aldrich) was added for 30 minutes at room
temperature. The plates were washed three times with PBS and
once with tap water. Only the colonies that were 2 mm2 or more
in diameter were counted. Each experiment was performed in
triplicate.

Differentiation
Adipogenic Differentiation
ASCs were cultured in six-well plates in CCM until 90% confluent.
Medium was then replaced with fresh medium containing adipogenic supplements, consisting of 1 M dexamethasone (SigmaAldrich), 5 g/ml insulin, 0.5 mM isobuytlmethylxanthine (Sigma-Aldrich), and 50 M indomethacin (Sigma-Aldrich) and
changed every third day. After 3 weeks, cells were fixed in 10%
formalin for 1 hour at 4°C and stained for 15 minutes at room
temperature with Oil Red O (Sigma-Aldrich), and images were
acquired on a Nikon Eclipse TE200 (Nikon, Melville, NY, http://
www.nikon.com) with a Nikon DXM1200F digital camera using
Nikon ACT-1 software, version 2.7. Images were acquired at a
magnification of ⫻10.

Osteogenic Differentiation
ASCs were cultured in six-well plates in CCM until 90% confluent,
and then the medium was replaced with medium containing osteogenic supplements, which consisted of 50 M ascorbate
2-phosphate (Sigma-Aldrich), 20 mM ␤-glycerol phosphate (Sigma-Aldrich), 50 ng/ml L-thyroxine sodium pentahydrate, and 1
nM dexamethasone. After 3 weeks, cells were fixed in 10% formalin for 1 hour at 4°C and stained for 10 minutes with 40 mM
alizarin red (pH 4.1) to visualize calcium deposition in the extracellular matrix. Images were acquired on a Nikon Eclipse TE200
with a Nikon DXM1200F digital camera using Nikon ACT-1 software, version 2.7. Images were acquired at a magnification of
⫻10.

Flow Cytometry
ASCs were harvested with 0.25% trypsin/1 mM EDTA (Gibco) for
4 minutes at 37°C. A total of 3 ⫻ 105 cells were concentrated by
centrifugation at 500g for 5 minutes, suspended in 100 l of PBS
containing 1% (wt/vol) bovine serum albumin, and incubated at
room temperature for 30 minutes with a panel of monoclonal
antibodies specific for CD106, CD29, Sca-1, CD31, CD11b, and
CD45. All monoclonal antibodies were purchased from BD
Pharmingen/BD Biosciences (San Jose, CA, http://www.
bdbiosciences.com). The samples were then analyzed by
FACScan (FACSCalibur; BD Biosciences) with CellQuest software.
The SVF was characterized using the same method with the
monoclonal antibodies to the following: CD14, CD16, CD18,
CD25, CD36, CD44, CD146, CD117, Mac-1, F4/80, and Foxp3 (all
purchased from eBioscience Inc., San Diego, CA, http://www.
STEM CELLS TRANSLATIONAL MEDICINE
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ebioscience.com) and CD3, CD4, CD8 CD11b, CD19, CD31, CD34,
and CD45 (purchased from BD Pharmingen). A minimum of
10,000 events were analyzed and compared with isotype controls.

EAE Induction and Treatment Protocols
All animal experiments were approved by Tulane University
School of Medicine’s Institutional Animal Care and Use Committee and were conducted in accordance with the U.S. Public
Health Service Policy on Human Care and Use of Laboratory Animals. Female C57Bl/6 mice, 6 – 8 weeks old, were purchased
from Charles River Laboratories (Wilmington, MA, http://www.
criver.com). Chronic EAE was induced in these animals by
subcutaneous immunization with 200 l of 200 ng MOG35–55
(AnaSpec, San Diego, CA, https://www.anaspec.com) mixed 1:1
in Complete Freund’s adjuvant with 8 mg/ml Mycobacterium tuberculosis H37RA (BD DIFCO, Franklin Lakes, NJ, http://www.bd.
com), and 100 l was injected subcutaneously at each side of the
base of the tail. Mice also received 100 l of 200 ng of pertussis
toxin (List Biological Laboratories, Campbell, CA, http://www.
listlabs.com) by intraperitoneal (i.p.) injection concomitantly and
again 2 days later. To evaluate the clinical and pathological efficacies of ASCs and SVF in chronic EAE, cells were administered
concomitantly with disease induction. Concurrently with disease induction, 100 l of 1 ⫻ 106 cells suspended in HBSS was
injected with a 27-gauge needle into the left side of the peritoneal cavity during EAE induction (day 0). Sham-treated,
EAE-induced mice received equal volumes of HBSS without
cells.

Clinical Scoring and Statistical Analysis
Naïve mice, EAE sham-treated mice, EAE mice treated with ASCs,
and EAE mice treated with SVF each had 12 mice per group and
were monitored daily for clinical signs of disease by three independent, blinded investigators. Clinical scores were based on a
scale of 0 –5, with a score of 0 indicating no disease; 1, limp tail
(loss of tail tone); 2, hind limb weakness; 3, partial hind limb
paralysis; 4, complete hind limb paralysis; and 5, moribund or
dead. No animals were excluded from analysis. Clinical scores are
presented as mean ⫾ SEM for each group, with dead animals
given a score of 5 on the day of death and for the remainder of
the experiment. Statistical analysis was determined by two-way
ANOVA on days 10 –14 and again on days 26 –30 using GraphPad
Prism version 4.0b (GraphPad Software, Inc., San Diego, CA,
http://www.graphpad.com). Significance was assumed if the p
value was ⱕ.01. The disease onset, disease incidence, and mean
maximum scores were recorded for each mouse and expressed
as mean ⫾ SD. The cumulative disease score was calculated by
summing the daily clinical score for each mouse during the
course of observation.

Tissue Processing and Histological Analysis
After 30 days after disease induction, 5 of the 12 animals per
group were euthanized by exposure to CO2 and perfused with
sterile PBS. The lumbar and sacral regions of the spinal cords
were removed, postfixed in 10% formalin (Thermo Fisher Scientific, Waltham, MA, http://www.thermofisher.com), and then
embedded in paraffin. Sections were cut at 6-m thickness on a
microtome and stained for hematoxylin and eosin (H&E; Thermo
Fisher Scientific) to reveal perivascular inflammatory infiltrates
and Luxol Fast Blue/Cresyl Violet (LFB; IHC World, Ellicott City,

www.StemCellsTM.com

791

MD, http://www.ihcworld.com) and Toluidine Blue (Thermo
Fisher Scientific) for myelin detection. Histological analysis was
performed on a Nikon Eclipse E800 microscope, acquired with
Slidebook version 5.0 software (Olympus, Center Valley, PA,
http://www.olympus-global.com), and analyzed using Fiji/
ImageJ software. Quantification for each stain was performed on
nine random sections per animal and five animals per group. All
images were analyzed by investigators blinded to the status of
the animal. The demyleination score was measured by the ratio
of area of intact myelein against the same values for the naïve
group, which was set to 1. An index of cellular debris was determined by the percentage of positive pixels divided by the percentage of positive pixels of the naïve group, which was set to 1.
The percentage of inflammatory infiltrates was measured by the
number of total cells (i.e., cells 5 m2) per field at a magnification
of ⫻400.

Cytokine Detection
At 30 days after disease induction, blood was collected from all
mice during intracardial perfusions. Cytokines were analyzed by
ELISA Immunoassay (Life Technologies), according to the manufacturer’s instructions. Briefly, serum was added in 96-well precoated plates and incubated at room temperature. After washing, a specific polyclonal antibody followed by substrate solution
was added, and the color development was measured at 450 nm
on a fluorescent microplate reader (FLUOstar optima; BMG
Labtech Inc., Durham, NC, http://www.bmglabtech.com). The
concentration of cytokines was calculated using the standard
curve. Statistical analysis using a two-tailed Student’s t test was
performed to evaluated differences between groups. Significance was assumed if the p value was ⱕ.05.

RESULTS
Characterization of the Fat Stromal Vascular Fraction
Subcutaneous adipose tissue obtained from 2– 6-month old
male eGFP transgenic mice was processed by collagenase digestion and differential centrifugation. Approximately 0.55 ⫾ 0.21 g
of adipose tissue was harvested per mouse, averaging 1.82 ⫻
106 ⫾ 9.9 ⫻ 104 mononuclear SVF cells per gram of adipose
tissue, with a viability between 89% and 94% when measured
with trypan blue (data not shown). After lysing red blood cells,
the cell populations in the SVF were analyzed for the presence of
lineage-specific markers via flow cytometry. The most abundant
populations detected were committed adipocyte progenitors
(26.26%) and ASCs (21.38%; Table 1). Additionally, 24.31% expressed leukocyte markers, 7.98% of cells expressed hematopoietic stem cell-like markers, and 4.20% expressed T-cell markers.
Cells below detectable levels (⬍2%) included the following: endothelial cells, vascular smooth muscle cells, B cells, mast cells,
granulocytes, monocytes, macrophages, natural killer cells, and
T-regulatory cells.

Characterization of Cultured Adipose-Derived Stem
Cells
In passage 1 after the initial plating of the SVF cells, ASCs appeared as a monolayer of large, flat cells and had a mean doubling time of 55.2 ⫾ 4.8 hours. At passage 2, cells acquired a
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Table 1. Characterization of stromal vascular fraction from
C57BL/6 mice
Cell type

Committed adipocyte
precursor
Leukocyte
ASC-like
HSC-like
T cell
T-regs
EC-like
Monocyte
Vascular smooth muscle cell
B cell
Mast cell
Granulocyte
Macrophage
NK cells

Cell surface profile

CD36⫹CD14⫺
CD45⫹CD34⫺
CD34⫹CD31⫺CD146⫺
CD45⫹CD34⫹
CD45⫹CD34⫺CD3⫹
CD4⫹Foxp3⫹CD25⫺
CD34⫹CD31⫹CD146⫹
CD14⫹CD45⫹
CD34dimCD31⫺CD146⫹
CD45⫹CD34⫺CD19⫹
CD45⫹CD34⫺CD117⫹
CD45⫹CD11b⫹
F4/80⫹Mac⫺1⫹CD11b⫹
CD8⫹CD16⫹CD3⫺

Percent
positive (%)

26.26
24.31
21.38
7.98
4.2
ND (1.99)
ND (1.99)
ND (1.99)
ND (1.99)
ND (1.99)
ND (1.99)
ND (1.99)
ND (1.99)
ND (1.99)

Abbreviations: ASC, adipose-derived stromal/stem cell; EC, endothelial
cell; HSC, hematopoietic stem cell; ND, not detected; NK, natural killer;
T-regs, T-regulatory cells.

spindle shape, appeared fibroblast-like, and had a mean doubling time of 81.6 ⫾ 4.8 hours. From passage 2 on, the morphological appearance and length of doubling time was maintained
during subsequent passages.
To demonstrate the multipotent differentiation potential
of ASCs, passage 2 cells were induced to differentiate into
adipogenic and osteogenic lineages. When ASCs were cultured in adipogenic medium for 3 weeks, more than 50% of
the cells became lipid-retaining cells that stained positive
with Oil Red O (Fig. 1A, middle). In osteogenic medium, more
than 30% of the cells were induced into an osteogenic lineage
confirmed by alizarin red staining (Fig. 1A, right). The ASCs
successfully generated colony-forming units by generating an
average of 20 ⫾ 4.6 colonies per plate when plated at 100
cells on a 10-cm2 plate (Fig. 1B). ASCs were phenotypically
defined as ⬎90% positive for CD29 and Sca-1, 60%– 80% positive for CD106, and negative (⬍ 2% positive) for CD31,
CD11b, and CD45 via flow cytometry (Fig. 1C).

Intraperitoneal Injection of ASCs or SVF Ameliorates
MOG35–55-Induced EAE
To evaluate whether the SVF cells or ASCs could affect disease
progression in an autoimmune disease such as EAE, a preventative protocol was investigated in which cells were administered
i.p. at the time of disease induction. Both SVF treatment and ASC
treatment halted disease progression when compared with controls treated with vehicle alone, resulting in a statistically significant reduction of cumulative disease scores (Fig. 2; Table 2). On
average, control mice developed the first clinical signs at 9 days
postinduction (DPI), peaked around day 14 with hind limb paralysis, and then presented a stable disease course, typical of this
model (Fig. 2; Table 2). Mice treated with ASCs had a slight but
statistically insignificant delayed onset of disease compared with
controls, with the average first clinical signs appearing at 9.3 DPI.
EAE mice treated with SVF cells had a drastic delay in disease
onset (14 DPI). It is important to note that only 3 of the 12 experimental animals treated with the SVF demonstrated clinical
signs, which first presented at 10 DPI. Although the mean maximum score of the ASC-treated group was not significantly different compared with SVF-treated mice (1.9 ⫾ 0.7 vs. 1.7 ⫾ 0.9,
respectively), the disease incidence was vastly altered. Only one
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of the SVF-treated mice reached a clinical score of 3, which presented only for 3 days, and then reduced to a clinical score of 2
for the remainder of the disease course (Fig. 2B). These data
suggest that the i.p. injection of ASCs or SVF cells results in delayed and reduced disease severity. Moreover, it also indicates
the SVF cells have a very potent neuroprotective effect in chronic
EAE.

Pathological Features Are Diminished With SVF or ASC
Treatment
To determine whether the reduced disease severity correlated
with pathological features, spinal cords from naïve, HBSStreated, ASC-treated, and SVF-treated EAE mice were stained
with Luxol Fast Blue to analyze regions of demyelination. Quantification was performed on nine sections per animal and five
animals per group. All images were analyzed by investigators
blinded to the status of the animal. Indexes were normalized to
the average value obtained in naïve mice (set to 1).
The extent of demyelinated regions was reduced in both the
SVF-treated (score of 0.77) and ASC-treated mice (score of 0.84)
compared with control EAE-treated mice (score of 0.68) (Fig. 3;
Table 2). Similarly, both treatment groups demonstrated reduced myelin breakdown products and debris compared with
controls (an index of 1.8 in ASC-treated mice and 1.0 in SVFtreated mice, compared with 6.1 in controls), consistent with a
neuroprotective effect of both cell therapies in EAE (Fig. 3; Table
2). The influx of immune infiltrates was measured by H&E staining of spinal cords. The percentage of infiltrating cells was significantly decreased in animals treated with either ASCs (7.9%) or
SVF (8.5%) compared with controls (14.6%), indicating that both
cell treatments are also capable of reducing inflammatory cell
infiltrates into the CNS during EAE induction (Fig. 3; Table 2).

SVF and ASCs Both Suppressed Interferon-␥ and
Interleukin-12 in the Sera of EAE Mice
Tumor necrosis factor-␣ (TNF␣), interleukin-12 (IL-12), and interferon-␥ (IFN-␥) are cytokines that have been shown to be responsible for Th1 cell stimulation and that play a central role in
the pathology of MS and EAE [39, 40]. To determine whether the
protective effect of ASC or SVF treatment was related to these
factors, levels in the sera were assayed by enzyme-linked immunosorbent assay. Although the IFN-␥ sera levels of ASC-treated
(51.33 pg/ml) and SVF-treated (54.46 pg/ml) mice were both
lower than in the control (77.71 pg/ml), the two experimental
groups were not statistically significant between each other. Neither ASC nor SVF treatment affected TNF␣ levels. The IL-12 sera
levels were significantly decreased in ASC-treated mice (79.26
pg/ml) and further decreased in SVF-treated mice (35.57 pg/ml)
compared with control mice (235.18 pg/ml) (Fig. 4). Collectively,
these data suggest that ASC and SVF treatment can decrease
serum levels of Th1-type inflammatory cytokines, such as IL-12
and IFN-␥.

DISCUSSION
Multipotent marrow stromal cells (MSCs) are a promising therapy for the treatment of autoimmune diseases of the CNS because of their immunomodulatory and neuroprotective effects.
BMSCs, the most studied type of MSCs, have demonstrated the
ability to ameliorate both chronic and relapsing-remitting EAE
[36, 41, 42]. In both experimental conditions, BMSCs have shown
STEM CELLS TRANSLATIONAL MEDICINE
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Figure 1. Characterization of mouse adipose-derived stem cells from C57Bl/6 stromal vascular fraction. Adipose-derived stromal/stem cells
(ASCs) were grown in complete culture medium (CCM) until they were 70% confluent and then switched to differentiation medium. After 21
days, cells were fixed and stained with alizarin red for osteogenesis and Oil Red O for adipogenesis. Representative images for each group are
shown (A). Magnification is ⫻10 for all panels. (B): CFUs were seeded at a density of 100 cells per 10-cm2 dish and incubated in CCM for
14 days. Cells were fixed and stained with crystal violet. A representative image is shown. (C): ASCs were stained with antibodies against
the indicated antigens and analyzed by flow cytometry. Each experiment was performed in triplicate. Abbreviation: CFU, colonyforming units.

Figure 2. Clinical evaluation of ASC or SVF treatment in myelin oligodendrocyte glycoprotein35–55-induced experimental autoimmune encephalitis.
(A): Improved clinical scores were seen in both ASC-treated (F) and SVF-treated () mice compared with controls (Œ). Values are means from three
independent reviewers. Bars indicate ⫾SEM. ⴱ, p ⱕ .01, comparing controls and ASC-treated mice; F, p ⱕ .01 between controls and SVF-treated
mice; Œ, p ⱕ .05 between SVF-treated and ASC-treated mice. (B): Left: The clinical scores at day 14 DPI show the distribution during peak disease,
demonstrating that the majority of SVF-treated mice displayed no symptoms and ASC-treated mice showed decreased symptoms. Right: The clinical
scores at the end of the course show that the treated groups stably maintained their reduced state of disease. Abbreviations: ASC, adipose-derived
stromal/stem cell; DPI, days postinjury; SVF, stromal vascular fraction.

to be effective by immune suppression exerted on autoreactive
B and T cells and inducing a Th2-polarized immune response [33,
35, 36, 42, 43]. However, the source and availability of MSCs is
becoming a crucial issue for their clinical application. Although
BMSCs have demonstrated promising results, the invasive nature of bone marrow biopsies may limit their practicality for
wider clinical applications. Since adipose tissue contains a large
number of ASCs, is easy to obtain in large quantities, and is easily
accessible, it has become an appealing cell source for regenerative medicine and tissue engineering. ASCs have been shown to
hold many of the same properties of BMSCs, such as the ability to
differentiate, inhibit T-cell activation and proliferation, and produce anti-inflammatory molecules, and have been shown to aid
in tissue repair through the secretion of cytokines [16]. The uncultured counterpart of ASCs, the SVF, is a particularly promising
candidate for regenerative medicine because the cells can be
isolated within hours of obtaining the lipoaspirate and no culture
expansion of the cells is required, which would reduce any potential risks associated with growing cells in vitro and remove the
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need for complex laboratories. In addition to the clinical risks of
ex vivo expansion, the variables used in cell culture, such as percentage and source of serum used, type of basal medium, medium supplements, culture surface substrate, cell seeding
density, passage number, and confluence of culture, are undoubtedly giving rise to contrasting and confusing results in research. They also contain a heterogeneous population of cells,
each type of which may independently contribute or work synergistically together, providing a beneficial effect.
Although the use of ASCs and SVF cells has been investigated
in alleviating symptoms in autoimmune diseases such as graftversus-host-disease, rheumatoid arthritis, Crohn’s disease, and
stroke, few studies have investigated ASCs or SVF cells in the
treatment of MS or its mouse model EAE [18, 30]. One group
showed that murine ASCs had a significant beneficial effect on
chronic EAE by acting simultaneously in the lymphoid organs as
well as the inflamed CNS and causing a dramatic change in antigen-specific T-cells [37]. Another group, Riordan et al., demonstrated improved function in MS patients treated with SVF [30].
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Table 2. Clinical features of EAE mice treated with ASCs or SVF
Treatment

Control
ASCs
SVF

Disease onset,
DPI (range)

Disease incidence,
no./no. total (%)

Mean maximum
score (range)

Cumulative
disease score

Percent
inflammatory
infiltrates (%)

Demyleination
score

Cellular
debris index

9.0 ⫾ 1.0a (7–10)
9.3 ⫾ 1.1 (8–10)
15 ⫾ 4.5 (10–30)

12/12 (100)
7/12 (58)
3/12 (25)

3.5 ⫾ 0.5b (3–4)
1.9 ⫾ 0.7 (0–4)
1.7 ⫾ 0.9 (1–3)

30.4 ⫾ 9.57a
13.05 ⫾ 9.6
9.4 ⫾ 9.0

14.62 ⫾ 6.6
7.9 ⫾ 5.5
8.54 ⫾ 6.9

0.68 ⫾ 0.3b
0.84 ⫾ 0.2
0.77 ⫾ 0.1

6.15 ⫾ 0.69b
1.83 ⫾ 0.2
1.06 ⫾ 0.2

p ⱕ .05 between control group and SVF-treated group.
p ⱕ .05 between control group and both experimental groups.
Abbreviations: ASC, adipose-derived stromal/stem cell; DPI, days postinduction; EAE, experimental autoimmune encephalitis; SVF, stromal vascular fraction.
a

b

Figure 3. Treatment with SVF or ASCs reduces cellular infiltration and tissue damage in experimental autoimmune encephalitis (EAE). Spinal
cords from Hanks’ balanced saline solution (HBSS)-treated, ASC-treated, SVF-treated, and naïve mice were obtained after euthanasia at 30
days postinjury and processed for histological staining using Luxol Fast Blue (LFB), Toluidine Blue (TB), and H&E. Quantification was performed
on nine random sections per animal and five animals per group. LFB staining identified multiple areas of demyelination in HBSS-treated EAE
mice but only scattered foci in both treated groups. Similarly, sections labeled with TB showed increased myelin debris and greater numbers
of demyelinated axons in the control mice compared with naïve or treated mice. Comparisons of the H&E images show a decrease in the
number of infiltrating immune cells in the spinal cord after administration of both ASCs and SVF. Abbreviations: ASC, adipose-derived
stromal/stem cell; H&E, hematoxylin and eosin; SVF, stromal vascular fraction.

Figure 4. Serum levels of inflammatory cytokines. At 30 days after disease induction, blood was collected from all mice during intracardial perfusion and
analyzed by ELISA Immunoassay. IL-12 levels were decreased in ASC-treated mice and further decreased in SVF-treated mice compared with control mice
(middle). Both treatment groups had a similar decrease in levels of IFN-␥ (left). No difference was seen in TNF␣ (right). Bars indicate ⫾SD. †, p ⱕ .05 between
controls and SVF-treated mice; ‡, p ⱕ .05 between controls and ASC-treated mice; ⴱ, p ⱕ .05 between treatment groups. Abbreviations: ASC, adiposederived stromal/stem cell; IFN-␥, interferon-␥; IL-12, interleukin-12; SVF, stromal vascular fraction; TNF␣, tumor necrosis factor-␣.
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However, the mechanism and effects of SVF therapy are not well
understood, and a comparison of uncultured versus ex vivo-expanded cells in the treatment of EAE has yet to be evaluated.
Furthermore, quantitative and statistically significant data are
lacking in animal models used to determine mechanism and effects.
This study is among the first to show that ASCs have a significant beneficial effect in preventing chronic EAE not only when ex
vivo-expanded but also without expansion. Although in both
cases, the amelioration of clinical scores was accompanied by a
strong reduction of spinal cord inflammation, demyelination,
and axonal damage, the SVF cells provided a significant reduction
in incidence of disease compared with their ex vivo-expanded
counterpart.
Characterizing the molecular mechanisms mediating ASCand SVF-based therapy is of critical importance to clinical applications and represents an important contribution to the understanding of ASC- and SVF-based therapy. IFN-␥ is a cytokine
associated with a number of autoinflammatory and autoimmune
diseases because of its role in Th1 cell stimulation, differentiation, and function via STAT1 and STAT4 pathways [39]. These
autoreactive T cells play a central role in the direct regulation of
T-cell activation and survival during autoimmune inflammation
in the pathology of MS and EAE [39, 40]. In this study, IFN-␥ was
reduced comparably between treatment groups. These results
point to an effector role of both ASCs and SVF cells, which would
occur during the early inflammatory phase of disease, supporting the possibility that ASCs and SVF could both affect the
generation of encephalitogenic effector T cells. Although BMSCs have been shown to reduce levels of IFN-␥ by direct contact, it is unclear whether ASCs and SVF cells use the same
mechanism [44]. Although the mechanisms mediating such
effects are still only partially understood, it is likely that they
involve both direct cell-to-cell contact and paracrine signaling
via soluble factors.
In addition to IFN-␥, IL-12 is responsible for Th1 cell stimulation, differentiation, and function and plays a central role in the
pathology of MS [39]. In this study, IL-12 was reduced in both
treatment groups, but levels were further reduced in the SVF
treatment group compared with the ASC treatment group. Although this is the first study to show that both ASC treatment
and SVF treatment have reduced levels of IL-12, BMSCs have
been shown to reduce levels of IL-12 in a chronic EAE model [44,
45]. Interestingly, murine BMSCs were shown to exert opposing effects on Th1 cells depending on the time of disease onset
and the level of effector T-cell activation, suppressing all T
cells when administered early in T-cell activation and able to
decrease IFN-␥ and increase IL-17 only when T cells became
activated [46].
These results indicate that IL-12 may play an important
mechanistic role during the increased potency of SVF-based
therapy. It is possible the SVF cells, beyond their ex vivo-expanded counterpart, have the ability to further reduce the level
of effector T-cell activation, keeping the disease progression in
a more naïve state by reducing IL-12 and, therefore, Th1 stimulation and differentiation. It remains unclear whether this is
a result of the ASCs being uncultured and retaining more of
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their in vivo properties, whether it is a result of administering
a heterogeneous population, or whether it is a product resulting from the interaction of ASCs with one of the other cell
types present.
Although BMSCs have been shown to reduce TNF␣ levels by
direct contact in vitro, this study showed that neither ASCs or SVF
cells affected TNF␣ levels in an EAE model [44]. This may be due
to BMSCs using a different mechanism or the cells being administered at different time points during T-cell activation and
differentiation. This also reiterates the speculation that the
timing of stem cell interaction with T cells may drastically
change immunomodulatory results and, therefore, disease
progression.

CONCLUSION
Further work needs to address whether it is the uncultured ASCs
in the SVF fraction that have such a potent effect or whether the
effect is a synergistic one with one or more of the other cell
populations found in the SVF fraction. Future studies also need
to further elucidate the mechanism, whether the injected therapeutic cells are causing a shift in the immune response in the
lymphatic system before other pathogenic events via IL-17 or
other notable cytokines, whether the injected therapeutic cells
are influencing the endothelium to prevent breakdown of the
blood-brain barrier and subsequent infiltration of immune cells
into the CNS, or whether the injected therapeutic cells are directly affecting the myelin breakdown. In conclusion, these findings show that when compared with ex vivo-expanded ASCs, SVF
cells are easier and safer to access, further delay and reduce EAE
disease course and pathology, and further reduce Th1-type cytokines. These results show that SVF cells have relevant therapeutic potential in an animal model of chronic MS and might
represent a valuable tool for stem cell-based therapy in chronic
inflammatory disease of the CNS.
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